Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis (Fibro-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02969759
Recruitment Status : Unknown
Verified November 2016 by University Hospital, Angers.
Recruitment status was:  Not yet recruiting
First Posted : November 21, 2016
Last Update Posted : November 23, 2016
Sponsor:
Information provided by (Responsible Party):
University Hospital, Angers

Tracking Information
First Submitted Date  ICMJE November 4, 2016
First Posted Date  ICMJE November 21, 2016
Last Update Posted Date November 23, 2016
Study Start Date  ICMJE November 2016
Estimated Primary Completion Date November 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 22, 2016)
Kinetics of fibroblast growth [ Time Frame: 24 hours ]
The growth rates of the fibroblast lines
Original Primary Outcome Measures  ICMJE
 (submitted: November 17, 2016)
Kinetics of fibroblast growth [ Time Frame: 24 hours ]
The growth rates of the fibroblast lines will be studied under various conditions thanks to an incubation system allowing automated growth measurement directly within the incubator
Change History Complete list of historical versions of study NCT02969759 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 22, 2016)
  • Mitochondrial metabolism [ Time Frame: 24 hours ]
    the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
  • Protéic metabolism [ Time Frame: 24 hours ]
    The presence of intracytoplasmic inclusion of target protein will be sought.
  • stress in senescence answer [ Time Frame: 24 hours ]
    the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.
Original Secondary Outcome Measures  ICMJE
 (submitted: November 17, 2016)
  • Mitochondrial metabolism [ Time Frame: 24 hours ]
    the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
  • Protéic metabolism [ Time Frame: 24 hours ]
    The presence of intracytoplasmic inclusion of target protein will be sought.
  • stress en senescence answer [ Time Frame: 24 hours ]
    the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Official Title  ICMJE Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Brief Summary

INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown. The average age of onset of ALS is about 60 years old, and the mean survival of patients is about 2 years. The disease is responsible for a progressive paralysis leading to death from respiratory failure. The only treatment available is the Riluzole, with a very modest efficiency on the progression of the disease. ALS is the third neurodegenerative disease, affecting 6000 persons in France, 150 000 in the world. Among the protagonists involved in the occurrence of the disease, mitochondrial perturbations and protein accumulations seem to be central elements.

OBJECTIVES: To precise the implication of energy and protein metabolism in the sporadic forms of ALS, to identify potential biomarkers of the disease and to test new therapies.

METHODS: The investigators will study cell growth, bioenergetics, mitochondrial dynamics, free-radicals production, presence of cytoplasmic inclusions, cytoskeleton structure and stress response in primary skin fibroblasts obtained from sporadic ALS patients. The study will be conducted over a period of three years in 3 centres specialized respectively in motor neuron diseases, mitochondrial metabolism and neuronal cytoskeleton.

PROSPECTS: If the investigators achieve to identify differences between ALS fibroblasts and controls, the results will be key elements to reinforce the hypothesis of a systemic disease with an important metabolic participation, to better define ALS pathophysiological mechanisms, to find potential biomarkers and to test new therapies.

Detailed Description

The investigators will study fibroblasts derived from sporadic ALS patients.

Clinical parameters will be collected such as sex, age, age of onset, clinical presentation, electrophysiological an respiratory parameters, treatments.

Patients and controls derived fibroblasts will be amplified and cultivated from skin biopsies.

Primary fibroblast cell cultures will be derived from skin biopsies obtained from control subjects and from the patients after obtaining written consent. Amplifications will be performed, from passage 1 to 6, allowing the time for cell cryopreservation of 10 samples per cell line. All experiments will be conducted on cells with similar passage numbers, ranging from 6 to 25, to avoid artefacts due to senescence.

Cell growth of each line will be monitored with the IncuCyte ZOOM® system (Essen Biosciences), a microscope gantry that resides in a cell incubator, and a networked external controller hard drive that gathers and processes image data. Cell growth will be automatically calculated at each time point using the relative cell density (ratio of the occupied area to the total area of the acquired regions).

The respiratory parameters of the fibroblasts will be monitored precisely with an high resolution oxygraph (OROBOROS). Enzymatic activity of each complex of the mitochondrial respiratory chain will be measured by spectrometry, and the mitochondrial membrane potential will be studied with fluorescence microscopy (TMRM probe). The investigators will also study mitochondrial dynamics and the architecture of mitochondrial network with fluorescence microscopy and super-resolution microscopy (SRM, Roper). The production of free radicals will be estimated with probes sensitive to oxidative stress. Finally, a metabolomic study (mass spectrometry QTRAP LC/MS/MS 5500 ABSciex) will be performed to characterise precisely the metabolites in the cells and to assess their metabolic profile.

The investigators will search for protein inclusions (intermediate filaments, TDP43, FUS, ubiquitin) with immuno-fluorescence technics. Western Blots will be performed to study the protein metabolism. The architecture of the cytoskeleton will be analysed in SRM and fluorescence microscopy, and the investigators will try to transfect fibroblasts in order to express Neurofilaments and study the consequences on the cytoskeleton and protein metabolism.

The investigators will study the response of the cells to the stress (hypoxia SCI-tive Dual, starvation), and to senescence (high passage numbers).

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Sporadic Amyotrophic Lateral Sclerosis
Intervention  ICMJE Other: Skin Biopsy
Study Arms  ICMJE
  • Patients
    ALS defined by El Escorial Criteria.
    Intervention: Other: Skin Biopsy
  • Controls
    Asymptomatic subjects with normal examination.
    Intervention: Other: Skin Biopsy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: November 17, 2016)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2019
Estimated Primary Completion Date November 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria :

  • a free signed an written consent
  • aged between 18 and 80 years old
  • ALS defined by El Escorial Criteria
  • normal neurological examination

Exclusion criteria:

  • comorbidity or treatment susceptible to impact on metabolism
  • differential diagnosis suspected, early and late forms (<6 month > 3 years)
  • ALS not defined by El Escorial Criteria
  • withdrawal of consent to participate
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02969759
Other Study ID Numbers  ICMJE 2016/36
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University Hospital, Angers
Study Sponsor  ICMJE University Hospital, Angers
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University Hospital, Angers
Verification Date November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP